Nessuna connessione a internet — viene mostrata la versione salvata della pagina.

Mesoblast Ltd

USUSD
← Allo screener

Mesoblast Ltd (US:MEOBF) — Biotechnology: Biological Products (No Diagnostic Substances). Numero di borse in cui sono quotate le azioni della società: 2. In questa pagina: prezzo e grafico, dividendi, principali azionisti e cronologia del numero di azioni.

Informazioni sull'azienda

Sito web
mesoblast.com
Settore
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Sede centrale
MELBOURNE, VICTORIA, Australia
Amministratore delegato
Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons)
Dipendenti
108
Azioni in circolazione
1.3 Mld al 2026-06-30
Flottante
861.1 Mln
Capitalizzazione di mercato
1.48 Mld USD
Insider
36.28%
Investitori istituzionali
17.44%
Settore (SIC)
Biological Products, (No Diagnostic Substances)
ISIN
AU000000MSB8
Descrizione

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers remestemcel-L-rknd, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, Duchenne muscular dystrophy, and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease; and Revascor for the treatment of hypoplastic left heart syndrome. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; MPC-150-IM for the treatment or prevention of chronic heart failure; Ryoncil for the treatment of pediatric SR-aGVHD; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM; Grünenthal GmbH to develop and commercialize MPC-06-ID for the treatment of chronic low back pain due to degenerative disc disease in patients; and JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.

Borse e ticker

BorsaTickerValutaPrezzoTipo
US USA StocksMEOBF OTCUSD1.39 +21.93%azioni ordinarie
AU Australian Securities ExchangeMSB principaleAUD—azioni ordinarie

Prezzo su 3 mesi

giorno di rialzo giorno di ribasso data di stacco del dividendo data di pagamentoPassa il mouse / tocca un giorno — prezzi di apertura, chiusura, massimo e minimo

Dividendi

Nessun pagamento di dividendi trovato (controllato 08.10.2026). Probabilmente la società non distribuisce dividendi.

Notizie di questa settimana

Ancora nessuna notizia dal sito della società.

pubblicità

Principali azionisti

DetentoreQuotaAzioniData del rapporto
Itescu (Silviu) (Chief E…≈6.23%80.84 Mln2026-07-17
VANGUARD STAR FUNDS-Vang…1.05%13.66 Mln2026-04-30
VANGUARD TAX-MANAGED FUN…0.62%8.01 Mln2026-06-30
iShares Trust-iShares Co…0.53%6.88 Mln2026-07-31
Rose (Eric) (Director (N…≈0.52%6.75 Mln2026-01-09
DFA INVESTMENT TRUST CO-…0.36%4.68 Mln2026-04-30
VANGUARD Intl Eqy. INDEX…0.27%3.51 Mln2026-04-30
iShares Trust-iShares MS…0.24%3.07 Mln2026-07-31
SCHWAB STRATEGIC TRUST-S…0.15%1.99 Mln2026-05-31
Dimensional ETF Trust-Di…0.11%1.38 Mln2026-04-30
iShares Trust-iShares Co…0.09%1.23 Mln2026-07-31
SPDR INDEX SHARES Fd.S-S…0.09%1.19 Mln2026-08-31
Bell (Jane Catherine) (D…≈0.05%622 4922025-02-28
Burns (William) (Indepen…≈0.02%226 2502025-10-21
Legato Capital Managemen…0.01%47 3802022-06-30
Cobley (Lyn Elizabeth) (…≈0%63 0002026-01-09